Intellectus Partners’s Iovance Biotherapeutics IOVA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $225K | Buy |
131,062
+14,850
| +13% | +$25.5K | 0.05% | 254 |
|
|
2025
Q1 | $387K | Buy |
116,212
+1,300
| +1% | +$4.33K | 0.1% | 208 |
|
|
2024
Q4 | $850K | Buy |
114,912
+1,583
| +1% | +$11.7K | 0.19% | 147 |
|
|
2024
Q3 | $1.06M | Sell |
113,329
-600
| -0.5% | -$5.63K | 0.27% | 108 |
|
|
2024
Q2 | $914K | Sell |
113,929
-4,000
| -3% | -$32.1K | 0.25% | 111 |
|
|
2024
Q1 | $1.75M | Buy |
117,929
+1,250
| +1% | +$18.5K | 0.46% | 62 |
|
|
2023
Q4 | $949K | Sell |
116,679
-3,600
| -3% | -$29.3K | 0.27% | 103 |
|
|
2023
Q3 | $547K | Buy |
120,279
+250
| +0.2% | +$1.14K | 0.17% | 163 |
|
|
2023
Q2 | $845K | Buy |
120,029
+11,150
| +10% | +$78.5K | 0.25% | 120 |
|
|
2023
Q1 | $665K | Buy |
108,879
+21,229
| +24% | +$130K | 0.21% | 137 |
|
|
2022
Q4 | $560K | Buy |
87,650
+41,673
| +91% | +$266K | 0.2% | 155 |
|
|
2022
Q3 | $440K | Hold |
45,977
| – | – | 0.16% | 168 |
|
|
2022
Q2 | $508K | Buy |
45,977
+8,377
| +22% | +$92.6K | 0.17% | 162 |
|
|
2022
Q1 | $626K | Sell |
37,600
-2,500
| -6% | -$41.6K | 0.19% | 143 |
|
|
2021
Q4 | $766K | Sell |
40,100
-18,700
| -32% | -$357K | 0.2% | 139 |
|
|
2021
Q3 | $1.45M | Buy |
58,800
+750
| +1% | +$18.5K | 0.35% | 76 |
|
|
2021
Q2 | $1.51M | Buy |
58,050
+15,500
| +36% | +$403K | 0.34% | 75 |
|
|
2021
Q1 | $1.35M | Buy |
42,550
+950
| +2% | +$30.1K | 0.37% | 73 |
|
|
2020
Q4 | $1.93M | Buy |
41,600
+6,850
| +20% | +$318K | 0.58% | 45 |
|
|
2020
Q3 | $1.14M | Buy |
34,750
+5,015
| +17% | +$165K | 0.43% | 67 |
|
|
2020
Q2 | $816K | Buy |
29,735
+17,900
| +151% | +$491K | 0.32% | 95 |
|
|
2020
Q1 | $354K | Buy |
11,835
+3,100
| +35% | +$92.7K | 0.17% | 147 |
|
|
2019
Q4 | $242K | Buy |
+8,735
| New | +$242K | 0.1% | 181 |
|